Abstract Library

#3541 Surgical treatment of type 1 gastric neuroendocrine tumors: A 20-years single center experience

Introduction: Gastric neuroendocrine tumors (g-NETs) are rare, differentiated and usually indolent lesions; they include 3 types based on their pathogenesis. Type 1 are usually treated endoscopically according to their size, depth of invasion and presence of lymph-node (LN) metastases, types 3 are generally treated surgically. There is no clear evidence of the most accurate staging strategy for regional LN metastases.

Conference:

Presenting Author: Bertani E

Authors: Colombo S, Fumagalli Romario U, Pisa E, Spada F, Fazio N,

Keywords: Pet, gastric neuroendocrine tumor, surgery,

#3246 Baseline albumin and neutrophil-to-lymphocyte ratio as predictive biomarkers of response to platinum-based therapy in patients with highly proliferative neuroendocrine carcinomas

Introduction: Neuroendocrine carcinomas (NECs) with ki-67/MIB1>55% show different responses to platinum-based therapy. Loss of Rb protein and KRAS mutation are markers of response, but it is unknown whether also clinical factors may have a predictive role.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Colombo E

Authors: Colombo E, Manca P, Prinzi N, Torchio M, Corti F,

Keywords: neuroendocrine carcinoma, albumin, neutrophil-to-lymphocyte ratio, neutropenia, platinum-based therapy, predictive biomarker, clinical biomarker, NECs,

#3152 Vasostatin-1 as pancreatic neuroendocrine tumor (PanNET) biomarker: A comparison between preoperative and postoperative measurements

Introduction: No reliable biomarkers are currently available for pancreatic neuroendocrine tumors (PanNET). Vasostatin-1 (VS-1), the N-terminal fragment of Chromogranin A (CgA), seems to be more reliable than CgA as its plasma levels are not altered by proton pump inhibitors. An association between preoperative VS-1 and pathological features of aggressiveness was previously reported in a cohort of patients with resected nonfunctioning (NF)-PanNET.

Conference: 18th Annual ENETS Concerence (2021)

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Manzoni M, Colombo B, Muffatti F,

Keywords: pancreatic neuroendocrine tumor, biomarker, chromogranin A, vasostatin-1,

#2934 Vasostatin-1 Predicts Recurrence in Patients Submitted to Surgery for Nonfunctioning Pancreatic Neuroendocrine Tumors (NF-PanNET)

Introduction: An association between preoperative Vasostatin-1 (VS-1) plasma level and pathological features of aggressiveness was previously reported in patients with surgically resected nonfunctioning (NF) PanNET.

Conference: 17th Annual ENETSConcerence (2020)

Presenting Author: Andreasi V

Authors: Andreasi V, Partelli S, Manzoni M, Muffatti F, Colombo B,

Keywords: pancreatic neuroendocrine tumors, biomarkers, chromogranin A, vasostatin 1, recurrence,

#1075 Filamin-A Is Required for Somatostatin Receptor 2 (SST2) Stabilization, Signaling and Angiogenesis Regulation in Gastroenteropancreatic Neuroendocrine Tumors

Introduction: Somatostatin receptor type 2 (SST2) is the main pharmacological target for GEP-NETs. A subset of patients is resistant to somatostatin analogs (SSa), although the molecular mechanisms responsible for resistance are poorly understood. Several studies identified cytoskeleton protein as determinant in receptor anchoring and signaling

Conference: 12th Annual ENETSConcerence (2015)

Presenting Author:

Authors: Vitali E, Cambiaghi V, Loiarro F, Zerbi A, Colombo P,

Keywords: FLNA, SST2, GEP-NET,